Major Innovex International (INVX) holder trims via 5.75M-share secondary sale

(Moderate)

(Neutral)

Form Type

SCHEDULE 13D/A

Rhea-AI Filing Summary

Innovex International’s major shareholder group updated its ownership after a large secondary stock sale. Selling stockholders agreed to sell 5,750,000 shares of common stock at $25.75 per share, and the underwriters fully exercised a 30-day option for another 862,500 shares.

The selling stockholders received $24.59125 per share, reflecting underwriting discounts. As part of the same transaction, Innovex repurchased 575,000 of these shares under its existing buyback program. After these moves, Amberjack-related entities and affiliates may be deemed to beneficially own 22,757,322 shares, or 33.2% of the 68,563,690 shares outstanding as of February 27, 2026.

Insights

Large secondary sale by existing funds, with Innovex simultaneously repurchasing shares, leaves Amberjack-affiliated group at a sizeable 33.2% stake.

The disclosure describes a secondary offering of 5,750,000 Innovex shares by existing investment funds at $25.75 per share, plus a fully exercised 862,500-share underwriters’ option. These are existing shares, so the sale primarily shifts ownership from the selling funds to public investors rather than creating new dilution.

Innovex also bought back 575,000 shares through its existing share repurchase program, slightly reducing the public float versus what it would otherwise have been. Post-transaction, Amberjack Capital Partners and related entities may be deemed to beneficially own 22,757,322 shares, or 33.2% of the 68,563,690 shares outstanding as of February 27, 2026, indicating continued concentrated ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/27/2026 - 08:54 PM

FAQ

How many Innovex (INVX) shares were sold in the secondary offering?

Existing Innovex shareholders sold 5,750,000 shares of common stock in the offering. In addition, underwriters fully exercised an option to purchase 862,500 extra shares, increasing the total number of shares sold by the selling stockholders into the market.

At what price were Innovex (INVX) shares sold and what did sellers receive?

Shares were offered to the public at $25.75 each. The selling stockholders received $24.59125 per share, reflecting underwriting discounts. This per-share amount is specifically disclosed as the net price received by the selling funds for the stock they sold.

Did Innovex (INVX) repurchase any shares in connection with this transaction?

Yes. Innovex agreed to repurchase 575,000 shares of common stock from the underwriters. The repurchase was made under the company’s existing share repurchase program and involved shares that were part of the same secondary offering structure.

What is Amberjack’s group ownership stake in Innovex (INVX) after the sale?

Amberjack Capital Partners and related entities may be deemed to beneficially own 22,757,322 Innovex shares. This represents 33.2% of the company’s 68,563,690 shares of common stock outstanding as of February 27, 2026, indicating a significant continuing ownership position.

How many Innovex (INVX) shares are outstanding after these transactions?

The filing states that 68,563,690 shares of Innovex common stock were outstanding as of February 27, 2026. This figure, drawn from the company’s prospectus supplement, is used to calculate the percentage ownership of the reporting Amberjack-related entities.

What lock-up restrictions apply to the Innovex (INVX) selling stockholders?

Selling stockholders entered a lock-up agreement running for 45 days after the date of the final prospectus. During this period, they agreed not to transfer Innovex common stock or related shares without underwriter consent, subject to specified exceptions detailed in the lock-up agreement.

Who were the underwriters for the Innovex (INVX) secondary offering?

J.P. Morgan Securities LLC acted as representative of the several underwriters. The underwriting agreement among Innovex, the selling stockholders, and these underwriters governed the 5,750,000-share offering and the fully exercised 862,500-share option described in the ownership amendment.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)

Innovex International, Inc.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

457651107

(CUSIP Number)

Jason Turowsky
Amberjack Capital Partners, L.P., 4400 Post Oak Parkway, Suite 2760
Houston, TX, 77002
(281) 605-3900

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

02/25/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Common Stock, par value $0.01 per share

(b)

Name of Issuer:

Innovex International, Inc.

(c)

Address of Issuer's Principal Executive Offices:

19120 Kenswick Drive, Humble, TEXAS , 77338.

Item 1 Comment:

This Amendment No. 2 to Schedule 13D amends and supplements the Schedule 13D filed by the undersigned with the Securities and Exchange Commission (the "SEC") on September 13, 2024, as amended by Amendment No. 1 dated March 6, 2025 (the "Schedule 13D"). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.

Item 4.

Purpose of Transaction

Item 4 of the Schedule 13D is hereby amended and supplemented by the addition of the following: Underwriting Agreement On February 25, 2026, the Issuer entered into an Underwriting Agreement (the "Underwriting Agreement") with Intervale Capital Fund II, L.P., Intervale Capital Fund II-A, L.P., Intervale Capital Fund III, L.P., Amberjack Capital Fund II, L.P., Innovex Co-Invest Fund, L.P., Innovex Co-Invest Fund II, L.P., (collectively, the "Seller Stockholders") and J.P. Morgan Securities LLC, as representative of the several underwriters listed on Schedule 1 thereto (the "Underwriters"), relating to the offer and sale by the Selling Stockholders of 5,750,000 shares of common stock, par value $0.01 per share, of the Issuer (the "Common Stock"), at a price to the public of $25.75 per share (the "Offering"). The Selling Stockholders received $24.59125 per share of Common Stock sold in the Offering, which is the public offering price less certain underwriting discounts. In addition, the Selling Stockholders granted the Underwriters a 30-day option to purchase up to an additional 862,500 shares of Common Stock ("Option"). On February 27, 2026, the Underwriters exercised the Option in full. Amberjack Capital Fund II, L.P. sold 4,902,244 shares of Common Stock to the Underwriters, consisting of (i) 4,262,820 shares of Common Stock in the Offering and (ii) 639,424 shares of Common Stock after the Underwriters' exercise of the Option. Innovex Co-Invest Fund II, L.P. sold 1,144,635 shares of Common Stock to the Underwriters, consisting of (i) 995,335 shares of Common Stock in the Offering and (ii) 149,300 shares of Common Stock after the Underwriters' exercise of the Option. Innovex Co-Invest Fund, L.P. sold 271,279 shares of Common Stock to the Underwriters, consisting of (i) 235,895 shares of Common Stock in the Offering and (ii) 35,384 shares of Common Stock after the Underwriters' exercise of the Option. Intervale Capital Fund II, L.P. sold 234,009 shares of Common Stock to the Underwriters, consisting of (i) 203,486 shares of Common Stock in the Offering and (ii) 30,523 shares of Common Stock after the Underwriters' exercise of the Option. Intervale Capital Fund II-A, L.P. sold 116 shares of Common Stock to the Underwriters, consisting of (i) 101 shares of Common Stock in the Offering and (ii) 15 shares of Common Stock after the Underwriters' exercise of the Option. Intervale Capital Fund III, L.P. sold 60,217 shares of Common Stock to the Underwriters, consisting of (i) 52,363 shares of Common Stock in the Offering and (ii) 7,854 shares of Common Stock after the Underwriters' exercise of the Option. The Underwriting Agreement also provided for the Issuer's purchase from the Underwriters of 575,000 shares of Common Stock that were subject to the Offering (the "Share Repurchase"). The Share Repurchase was made pursuant to the Issuer's existing share repurchase program. The Offering and the Share Repurchase closed on February 27, 2026. The Underwriting Agreement contains customary representations and warranties, agreements and obligations, closing conditions and termination provisions. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, which is incorporated by reference as Exhibit 99.1 and is incorporated herein by reference. Lock-up Agreement On February 25, 2026, the Issuer entered into a lock-up agreement with the Selling Stockholders (the "Lockup Agreement"). Under the Lockup-Agreement, the Selling Stockholders agreed to not and not to cause any affiliates to, during the period beginning on the date of the Lock-up Agreement and ending at the close of business 45 days after the date of the final prospectus relating the Offering, to transfer any Common Stock or any shares underlying such Common Stock without the prior written consent of the Underwriters, subject to certain exceptions. The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Form of Lock-Up Agreement, which is incorporated by reference as Exhibit 99.2 and is incorporated herein by reference.

Item 5.

Interest in Securities of the Issuer

(a)

Item 5 of the Schedule 13D is hereby amended and restated as follows: Items 7 through 11 and 13 of each of the cover pages of this Schedule 13D are incorporated herein by reference. Such information is based on 68,563,690 shares of Common Stock of the Issuer outstanding as of February 27, 2026, as reported in the Issuer's Prospectus Supplement filed with the SEC on February 27, 2026. i. Amberjack Capital Fund II As of the date hereof, Amberjack Capital Fund II beneficially owns 16,871,374 shares of Common Stock. Percentage: 24.6% ii. Innovex Co-Invest Fund II As of the date hereof, Innovex Co-Invest Fund II beneficially owns 3,939,330 shares of Common Stock. Percentage: 5.7% iii. Innovex Co-Invest Fund As of the date hereof, Innovex Co-Invest Fund beneficially owns 933,624 shares of Common Stock. Percentage: 1.4% iv. Intervale Capital Fund II As of the date hereof, Intervale Capital Fund II beneficially owns 805,355 shares of Common Stock. Percentage: 1.2% v. Intervale Capital Fund II-A As of the date hereof, Intervale Capital Fund II-A beneficially owns 399 shares of Common Stock. Percentage: 0.0% vi. Intervale Capital Fund III As of the date hereof, Intervale Capital Fund III beneficially owns 207,240 shares of Common Stock. Percentage: 0.3% vii. Amberjack Capital GP II Amberjack Capital GP II, as the general partner of Amberjack Capital Fund II, may be deemed the beneficial owner of the 16,871,374 shares of Common Stock owned by Amberjack Capital Fund II. Percentage: 24.6% viii. Innovex Co-Invest Fund II GP Innovex Co-Invest Fund II GP, as the general partner of Innovex Co-Invest Fund II, may be deemed the beneficial owner of the 3,939,330 shares of Common Stock owned by Innovex Co-Invest Fund II. Percentage: 5.7% ix. Innovex Co-Invest Fund GP Innovex Co-Invest Fund GP, as the general partner of Innovex Co-Invest Fund, may be deemed the beneficial owner of the 933,624 shares of Common Stock owned by Innovex Co-Invest Fund. Percentage: 1.4% x. Intervale Capital GP II Intervale Capital GP II, as the general partner of Intervale Capital Fund II and Intervale Capital Fund II-A, may be deemed the beneficial owner of 805,754 shares of Common Stock, comprised of the (i) 805,355 shares of Common Stock owned by Intervale Capital Fund II and (ii) 399 shares of Common Stock owned by Intervale Capital Fund II-A. Percentage: 1.2% xi. Intervale Capital GP III Intervale Capital GP III, as the general partner of Intervale Capital Fund III, may be deemed the beneficial owner of the 207,240 shares of Common Stock owned by Intervale Capital Fund III. Percentage: 0.3% xii. Amberjack Capital Associates II Amberjack Capital Associates II, as the general partner of Amberjack Capital GP II, may be deemed the beneficial owner of the 16,871,374 shares of Common Stock owned by Amberjack Capital Fund II. Percentage: 24.6% xiii. Innovex Co-Invest Associates Innovex Co-Invest Associates, as the general partner of Innovex Co-Invest Fund II GP and Innovex Co-Invest Fund GP, may be deemed the beneficial owner of 4,872,954 shares of Common Stock, comprised of the (i) 3,939,330 shares of Common Stock owned by Innovex Co-Invest Fund II and (ii) 933,624 shares of Common Stock owned by Innovex Co-Invest Fund. Percentage: 7.1% xiv. Intervale Capital Associates II Intervale Capital Associates II, as the general partner of Intervale Capital GP II, may be deemed the beneficial owner of 805,754 shares of Common Stock, comprised of the (i) 805,355 shares of Common Stock owned by Intervale Capital Fund II and (ii) 399 shares of Common Stock owned by Intervale Capital Fund II-A. Percentage: 1.2% xv. Intervale Capital Associates III Intervale Capital Associates III, as the general partner of Intervale Capital GP III, may be deemed the beneficial owner of the 207,240 shares of Common Stock owned by Intervale Capital Fund III. Percentage: 0.3% xvi. Amberjack Capital Partners Amberjack Capital Partners, as the sole member of Amberjack Capital Associates II, Innovex Co-Invest Associates, Intervale Capital Associates II, and Intervale Capital Associates III, may be deemed the beneficial owner of 22,757,322 shares of Common Stock, comprised of the (i) 16,871,374 shares of Common Stock owned by Amberjack Capital Fund II, (ii) 3,939,330 shares of Common Stock owned by Innovex Co-Invest Fund II, (iii) 933,624 shares of Common Stock owned by Innovex Co-Invest Fund, (iv) 805,355 shares of Common Stock owned by Intervale Capital Fund II, (v) 399 shares of Common Stock owned by Intervale Capital Fund II-A, and (vi) 207,240 shares of Common Stock owned by Intervale Capital Fund III. Percentage: 33.2% xvii. Amberjack Management Amberjack Management, as the general partner of Amberjack Capital Partners, may be deemed the beneficial owner of 22,757,322 shares of Common Stock, comprised of the (i) 16,871,374 shares of Common Stock owned by Amberjack Capital Fund II, (ii) 3,939,330 shares of Common Stock owned by Innovex Co-Invest Fund II, (iii) 933,624 shares of Common Stock owned by Innovex Co-Invest Fund, (iv) 805,355 shares of Common Stock owned by Intervale Capital Fund II, (v) 399 shares of Common Stock owned by Intervale Capital Fund II-A, and (vi) 207,240 shares of Common Stock owned by Intervale Capital Fund III. Percentage: 33.2% xviii. Jason Turowsky Jason Turowsky, as managing partner of Amberjack Management, may be deemed the beneficial owner of 22,757,322 shares of Common Stock, comprised of the (i) 16,871,374 shares of Common Stock owned by Amberjack Capital Fund II, (ii) 3,939,330 shares of Common Stock owned by Innovex Co-Invest Fund II, (iii) 933,624 shares of Common Stock owned by Innovex Co-Invest Fund, (iv) 805,355 shares of Common Stock owned by Intervale Capital Fund II, (v) 399 shares of Common Stock owned by Intervale Capital Fund II-A, and (vi) 207,240 shares of Common Stock owned by Intervale Capital Fund III. Percentage: 33.2%

(b)

i. Amberjack Capital Fund II 1. Sole power to vote or direct vote: 16,871,374 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 16,871,374 4. Shared power to dispose or direct the disposition: 0 ii. Innovex Co-Invest Fund II 1. Sole power to vote or direct vote: 3,939,330 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 3,939,330 4. Shared power to dispose or direct the disposition: 0 iii. Innovex Co-Invest Fund 1. Sole power to vote or direct vote: 933,624 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 933,624 4. Shared power to dispose or direct the disposition: 0 iv. Intervale Capital Fund II 1. Sole power to vote or direct vote: 805,355 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 805,355 4. Shared power to dispose or direct the disposition: 0 v. Intervale Capital Fund II-A 1. Sole power to vote or direct vote: 399 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 399 4. Shared power to dispose or direct the disposition: 0 vi. Intervale Capital Fund III 1. Sole power to vote or direct vote: 207,240 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 207,240 4. Shared power to dispose or direct the disposition: 0 vii. Amberjack Capital GP II 1. Sole power to vote or direct vote: 16,871,374 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 16,871,374 4. Shared power to dispose or direct the disposition: 0 viii. Innovex Co-Invest Fund II GP 1. Sole power to vote or direct vote: 3,939,330 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 3,939,330 4. Shared power to dispose or direct the disposition: 0 ix. Innovex Co-Invest Fund GP 1. Sole power to vote or direct vote: 933,624 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 933,624 4. Shared power to dispose or direct the disposition: 0 x. Intervale Capital GP II 1. Sole power to vote or direct vote: 805,754 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 805,754 4. Shared power to dispose or direct the disposition: 0 xi. Intervale Capital GP III 1. Sole power to vote or direct vote: 207,240 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 207,240 4. Shared power to dispose or direct the disposition: 0 xii. Amberjack Capital Associates II 1. Sole power to vote or direct vote: 16,871,374 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 16,871,374 4. Shared power to dispose or direct the disposition: 0 xiii. Innovex Co-Invest Associates 1. Sole power to vote or direct vote: 4,872,954 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 4,872,954 4. Shared power to dispose or direct the disposition: 0 xiv. Intervale Capital Associates II 1. Sole power to vote or direct vote: 805,754 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 805,754 4. Shared power to dispose or direct the disposition: 0 xv. Intervale Capital Associates III 1. Sole power to vote or direct vote: 207,240 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 207,240 4. Shared power to dispose or direct the disposition: 0 xvi. Amberjack Capital Partners 1. Sole power to vote or direct vote: 22,757,322 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 22,757,322 4. Shared power to dispose or direct the disposition: 0 xvii. Amberjack Management 1. Sole power to vote or direct vote: 22,757,322 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 22,757,322 4. Shared power to dispose or direct the disposition: 0 xviii. Jason Turowsky 1. Sole power to vote or direct vote: 22,757,322 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 22,757,322 4. Shared power to dispose or direct the disposition: 0

(c)

The information in Item 4 is incorporated herein by reference. Except as disclosed in this Schedule 13D, there have been no transactions in the shares of Common Stock effected by the Reporting Persons on behalf of the Funds in the past 60 days.

(d)

Not applicable.

(e)

Not applicable.

Item 7.

Material to be Filed as Exhibits.

99.1 Underwriting Agreement, dated as of February 25, 2026, by and among the Issuer, the Seller Stockholders and J.P. Morgan Securities LLC (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K (File No. 001-13439), filed with the Securities and Exchange Commission on February 27, 2026). 99.2 Form of Lock-up Agreement.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Amberjack Capital Fund II, L.P.

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner of Amberjack Capital Associates II, LLC, the general partner of Amberjack Capital GP II, L.P., its general partner
Date:	02/27/2026

Innovex Co-Invest Fund II, L.P.

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner of Innovex Co-Invest Associates, LLC, the general partner of Innovex Co-Invest Fund II GP, L.P., its general partner
Date:	02/27/2026

Innovex Co-Invest Fund, L.P.

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner of Innovex Co-Invest Associates, LLC, the general partner of Innovex Co-Invest Fund GP, L.P., its general partner
Date:	02/27/2026

Intervale Capital Fund II, L.P.

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner of Intervale Capital Associates II, LLC, the general partner of Intervale Capital GP II, L.P., its general partner
Date:	02/27/2026

Intervale Capital Fund II-A, L.P.

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner of Intervale Capital Associates II, LLC, the general partner of Intervale Capital GP II, L.P., its general partner
Date:	02/27/2026

Intervale Capital Fund III, L.P.

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner of Intervale Capital Associates III, LLC, the general partner of Intervale Capital GP III, L.P., its general partner
Date:	02/27/2026

Amberjack Capital GP II, L.P.

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner of Intervale Capital Associates II, LLC, its general partner
Date:	02/27/2026

Innovex Co-Invest Fund II GP, L.P.

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner of Innovex Co-Invest Associates, LLC, its general partner
Date:	02/27/2026

Innovex Co-Invest Fund GP, L.P.

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner of Innovex Co-Invest Associates, LLC, its general partner
Date:	02/27/2026

Intervale Capital GP II, L.P.

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner of Intervale Capital Associates II, LLC, its general partner
Date:	02/27/2026

Intervale Capital GP III, L.P.

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner of Intervale Capital Associates III, LLC, its general partner
Date:	02/27/2026

Amberjack Capital Associates II, LLC

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner
Date:	02/27/2026

Innovex Co-Invest Associates, LLC

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner
Date:	02/27/2026

Interval Capital Associates II, LLC

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner
Date:	02/27/2026

Intervale Capital Associates III, LLC

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner
Date:	02/27/2026

Amberjack Capital Partners, L.P.

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner of Amberjack Management, LLC, its general partner
Date:	02/27/2026

Amberjack Management, LLC

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky / Partner
Date:	02/27/2026

Turowsky Jason

Signature:	/s/ Jason Turowsky
Name/Title:	Jason Turowsky /Self
Date:	02/27/2026

Source: View Original Filing on SEC EDGAR

Major Innovex International (INVX) holder trims via 5.75M-share secondary sale

Rhea-AI Filing Summary

Positive

Negative

Insights

FAQ

How many Innovex (INVX) shares were sold in the secondary offering?

At what price were Innovex (INVX) shares sold and what did sellers receive?

Did Innovex (INVX) repurchase any shares in connection with this transaction?

What is Amberjack’s group ownership stake in Innovex (INVX) after the sale?

How many Innovex (INVX) shares are outstanding after these transactions?

What lock-up restrictions apply to the Innovex (INVX) selling stockholders?

Who were the underwriters for the Innovex (INVX) secondary offering?

Major Innovex International (INVX) holder trims via 5.75M-share secondary sale

Rhea-AI Filing Summary

Positive

Negative

Insights

Equity ownership and capital-markets analyst neutral

FAQ

How many Innovex (INVX) shares were sold in the secondary offering?

At what price were Innovex (INVX) shares sold and what did sellers receive?

Did Innovex (INVX) repurchase any shares in connection with this transaction?

What is Amberjack’s group ownership stake in Innovex (INVX) after the sale?

How many Innovex (INVX) shares are outstanding after these transactions?

What lock-up restrictions apply to the Innovex (INVX) selling stockholders?

Who were the underwriters for the Innovex (INVX) secondary offering?